GW Pharmaceuticals Plc (GWPH)

155.87
0.13 0.08
NASDAQ : Health Technology
Prev Close 155.74
Open 157.72
Day Low/High 151.32 / 158.00
52 Wk Low/High 90.14 / 179.65
Volume 467.51K
Avg Volume 466.80K
Exchange NASDAQ
Shares Outstanding 30.45M
Market Cap 5.25B
EPS -10.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
INVESTOR ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016

INVESTOR ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased GW Pharmaceuticals plc (Nasdaq:GWPH) securities...

Jim Cramer's 'Mad Money' Recap: This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: This Week's Game Plan

With a slightly less brutal backdrop for the stock market, Cramer says earnings can once again command the spotlight for this week's trading.

'Mad Money' Lightning Round: Cramer Likes FedEx and UPS

'Mad Money' Lightning Round: Cramer Likes FedEx and UPS

Cramer likes FedEx in addition to Dollar General and Dollar Tree, and thinks Cypress Semiconductor is too cheap.

STOCK ALERT: Rosen Law Firm Reminds GW Pharmaceuticals Plc Investors Of Important Deadline In Class Action - GWPH

STOCK ALERT: Rosen Law Firm Reminds GW Pharmaceuticals Plc Investors Of Important Deadline In Class Action - GWPH

Rosen Law Firm, a global investor rights law firm, reminds purchasers of GW Pharmaceuticals plc securities (NASDAQ: GWPH) from December 4, 2014 through January 8, 2016, both dates inclusive (the "Class Period") of the...

Mood Swing Tape Continues

Market internals hit upside trend day levels just one day after hitting downside trend day levels.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against GW Pharmaceuticals Plc - GWPH

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against GW Pharmaceuticals Plc - GWPH

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of GW Pharmaceuticals plc (NASDAQ:GWPH) securities from December 4, 2014 through January 8, 2016,...

8 Things That Could Lift Biotech Stocks Out of Bear Market

8 Things That Could Lift Biotech Stocks Out of Bear Market

Biotech stocks are buried in a deep hole. To climb out, companies will have to generate some positive news.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud By GW Pharmaceuticals Plc And Certain Officers And Directors

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud By GW Pharmaceuticals Plc And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of GW Pharmaceuticals plc ("GW Pharmaceuticals" or "the Company") (NASDAQ:GWPH) concerning possible violations of federal securities laws by the...

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.

This Is the Only Stock to Buy Right Now to Profit From Legalized Weed

This Is the Only Stock to Buy Right Now to Profit From Legalized Weed

Legalized cannabis is now the fastest-growing industry in the U.S. We highlight a "green rush" stock that analysts say will soar 124% next year.

'Mad Money' Lightning Round: It's OK to Buy Pandora Media Now

'Mad Money' Lightning Round: It's OK to Buy Pandora Media Now

Cramer is sticking with Bristol-Myers, is avoiding Marathon Oil and is a believer in Cypress Semiconductor.

Jim Cramer's 'Mad Money' Recap: Winners, Losers and the Chasm Between Them

Jim Cramer's 'Mad Money' Recap: Winners, Losers and the Chasm Between Them

There are haves and have-nots in every industry this year, Cramer says.

'Mad Money' Lightning Round: Take Mattel Over Hasbro

'Mad Money' Lightning Round: Take Mattel Over Hasbro

Cramer calls Raytheon one of the best military plays and GW Pharmaceuticals one of the most speculative stocks.

Jim Cramer's 'Mad Money' Recap: Play the Hand You're Dealt

Jim Cramer's 'Mad Money' Recap: Play the Hand You're Dealt

While some investors are throwing back all their cards and giving up, the skilled players are keeping what works and augmenting their hands with what'll keep working, Cramer says.

Jim Cramer Answers 8 Questions From Viewers Including CEO Henry Blodget

Jim Cramer Answers 8 Questions From Viewers Including CEO Henry Blodget

From the floor of the NSYE on Wednesday, Jim Cramer answered viewers' questions on the stock market, including questions on Tesla, Chipotle, Ford, PayPal, Under Armour and Lockheed Martin.

Jim Cramer Fields Questions From Viewers Including Henry Blodget

Jim Cramer Fields Questions From Viewers Including Henry Blodget

TheStreet's Jim Cramer tackled viewer questions on the economy from the NYSE Wednesday. His first viewer question was from Henry Blodget, an investor and CEO of Business Insider.

GW Pharmaceuticals Announces Date And Time Change For Q4 And Year-End 2015 Financial Results And Conference Call

GW Pharmaceuticals Announces Date And Time Change For Q4 And Year-End 2015 Financial Results And Conference Call

-Change to After Market on 7 December to Facilitate Inclusion of Additional Epidiolex Data-

'Mad Money' Lightning Round: Northrop Grumman, Lockheed Martin Both Terrific

'Mad Money' Lightning Round: Northrop Grumman, Lockheed Martin Both Terrific

Cramer likes Johnson & Johnson, Stryker and Edwards Lifesciences, while avoiding all Chinese stocks.

Jim Cramer's 'Mad Money' Recap: Winners Remain When Rates Rise

Jim Cramer's 'Mad Money' Recap: Winners Remain When Rates Rise

When interest rates begin to rise, it may be harder to find winners, Cramer said. But only a pessimist would stop looking.